Global Study of HyQvia Treatment in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy CIDP Switching to HyQvia in Routine Care

What this Trial Is About

Researchers are studying adults with Chronic Inflammatory Demyelinating Polyradiculoneuropathy CIDP to understand why they choose certain treatments, particularly switching to HyQvia, and how satisfied they are with HyQvia and their previous therapies. The study also explores how CIDP affects work productivity and daily activities, as well as the signs and symptoms of CIDP. The research collects information on medical problems or side effects during HyQvia treatment, its effectiveness, and healthcare needs such as emergency or hospital visits. Participants are divided into two groups those who plan to switch to HyQvia within six weeks after joining the study and those who have already switched within six weeks before joining. Data will be collected over 12 months through interviews, medical record reviews, and questionnaires. Treatment follows the doctors usual clinical care and is not controlled by the study. During the study, participants will complete questionnaires about their treatment preferences, satisfaction, quality of life, disability, and work productivity at the start and throughout the 12 months. Researchers will monitor any adverse effects and changes in physical strength and disability scores. Healthcare use and treatment details will be tracked regularly to understand the real-world use and impact of HyQvia in managing CIDP.

A Study of HyQvia in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) in Routine Clinical Care